Apellis Pharmaceuticals, Inc.
APLS
$17.97
$0.080.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.00B | 1.02B | 754.65M | 775.84M | 781.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00B | 1.02B | 754.65M | 775.84M | 781.37M |
| Cost of Revenue | 398.09M | 411.35M | 440.76M | 461.16M | 445.29M |
| Gross Profit | 605.69M | 605.05M | 313.89M | 314.68M | 336.08M |
| SG&A Expenses | 550.27M | 524.64M | 503.95M | 500.89M | 501.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 948.36M | 935.99M | 944.71M | 962.06M | 946.35M |
| Operating Income | 55.43M | 80.41M | -190.06M | -186.22M | -164.98M |
| Income Before Tax | 24.11M | 46.68M | -226.49M | -222.35M | -196.72M |
| Income Tax Expenses | 1.72M | 1.70M | 1.69M | 1.33M | 1.16M |
| Earnings from Continuing Operations | 22.39 | 44.99 | -228.17 | -223.68 | -197.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.39M | 44.99M | -228.17M | -223.68M | -197.88M |
| EBIT | 55.43M | 80.41M | -190.06M | -186.22M | -164.98M |
| EBITDA | 56.99M | 82.08M | -188.26M | -184.42M | -163.18M |
| EPS Basic | 0.17 | 0.34 | -1.82 | -1.79 | -1.60 |
| Normalized Basic EPS | 0.12 | 0.22 | -1.13 | -1.10 | -0.98 |
| EPS Diluted | 0.11 | 0.31 | -1.82 | -1.79 | -1.60 |
| Normalized Diluted EPS | 0.09 | 0.19 | -1.13 | -1.10 | -0.98 |
| Average Basic Shares Outstanding | 504.56M | 502.42M | 500.23M | 498.11M | 495.62M |
| Average Diluted Shares Outstanding | 508.21M | 506.07M | 500.23M | 498.11M | 495.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |